XML 20 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Agreements (Details Textual) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Research Revenue $ 0 $ 0 $ 0 $ 186,233      
Research and Development Expense, Total 1,568,969 547,821 2,657,936 1,696,428      
Other Companies [Member] | Collaborative Arrangement [Member]
             
Research and Development Expense, Total 940,139 129,012 1,478,534 707,086      
Abbott Products, Inc. [Member] | Collaborative Arrangement [Member]
             
Upfront License Fees Received             4,000,000
Milestone Payments Received         3,000,000 2,000,000  
License Fees And Milestones Revenue       7,523,437      
Research Revenue 0 0 0 186,233      
Agreement Termination Date       Mar. 29, 2012      
Description Of Royalty Payment     All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1.5% royalty on net sales should Lipocine decide to use certain Solvay/Abbott formulations or a perpetual 1% royalty on net sales should Lipocine use data generated during the term of the Solvay/Abbott agreement in any regulatory filings for a product.        
Maximum royalty payment for the first two calendar years     1,000,000        
Conditional Royalty Reduction Percentage     50.00%        
Collaborative Product Development Agreement With Nexgen Pharma, Inc. [Member] | Research and Development Expense [Member]
             
Reimbursement Revenue $ 0 $ 0 $ 468,348 $ 397,852